Enhancing Week-long Psychological Treatment for PTSD With Ketamine
Phase 2
162
about 8 years
21–70
1 site in CT
What this study is about
This trial is testing if a combination of ketamine, midazolam, and intensive trauma-focused psychotherapy will be more effective in treating post-traumatic stress disorder (PTSD) than usual care. The goal is to see if this week-long treatment can provide significant relief that would normally take months to achieve. Researchers are also studying the brain changes caused by this clinical trial.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ketamine
- 2.Take Midazolam
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), midazolam (Benzodiazepine; short-acting)
injection
Primary: To determine if ketamine + exposure therapy results in clinical improvement in PTSD symptoms which are significantly greater than midazolam + exposure therapy (Phase 2; combined R61/R33 data)
Secondary: Change from baseline to 90 days post treatment in Beck Depression Inventory (BDI-II)
Psychiatry / Mental Health